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activation. ABHD6 is a potential
therapeutic target for obesity and type 2
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Suppression of a/b-domain hydrolase-6 (ABHD6),
a monoacylglycerol (MAG) hydrolase, promotes
glucose-stimulated insulin secretion by pancreatic
b cells. We report here that high-fat-diet-fed
ABHD6-KO mice show modestly reduced food
intake, decreased body weight gain and glycemia,
improved glucose tolerance and insulin sensitivity,
and enhanced locomotor activity. ABHD6-KO mice
also show increased energy expenditure, cold-
induced thermogenesis, brown adipose UCP1
expression, fatty acid oxidation, and white adipose
browning. Adipose browning and cold-induced ther-
mogenesis are replicated by the ABHD6 inhibitor
WWL70 and by antisense oligonucleotides targeting
ABHD6. Our evidence suggests that one mechanism
bywhich the lipolysis derived 1-MAG signals intrinsic
and cell-autonomous adipose browning is via
PPARa and PPARg activation, and that ABHD6 regu-
lates adipose browning by controlling signal compe-
tent 1-MAG levels. Thus, ABHD6 regulates energy
homeostasis, brown adipose function, and white ad-
ipose browning and is a potential therapeutic target
for obesity and type 2 diabetes.INTRODUCTION
The glycerolipid/free fatty acid cycle, which generates signaling
molecules within its lipolysis and lipogenesis segments, plays a
role in the regulation of fat storage and mobilization, insulin
secretion and action, non-shivering thermogenesis, and energy
homeostasis (Nielsen et al., 2014; Prentki and Madiraju, 2008;
Zechner et al., 2012). Lipolysis of triglycerides to diacylglycerol,
monoacylglycerol (MAG), and glycerol plus fatty acids is cata-
lyzed by the sequential action of adipose triglyceride lipase, hor-2872 Cell Reports 14, 2872–2888, March 29, 2016 ª2016 The Authormone sensitive lipase, and MAG lipase (Prentki and Madiraju,
2008; Zechner et al., 2012). Although MAG lipase is thought to
be the major MAG hydrolyzing enzyme in many tissues, intracel-
lular breakdown of MAG can also be catalyzed by membrane
bound a/b-hydrolase domain 6 (ABHD6) (Blankman et al.,
2007). We recently showed ABHD6 as the major MAG hydrolase
in pancreatic b cells and that suppression of ABHD6 results in
elevated islet 1-MAG levels with enhanced glucose-stimulated
insulin secretion through the activation of exocytosis facilitating
protein Munc13-1 (Zhao et al., 2014). Whole-body deletion of
MAG lipase in mice enhances insulin sensitivity and glucose
tolerancewithout affecting bodyweight gain or food intake under
a high-fat diet (HFD) condition (Taschler et al., 2011). A recent
study showed that ABHD6 controls the levels of anti-inflamma-
tory bioactive lipid prostaglandin D2-glycerol ester and that
ABHD6 suppression by a pharmacological agent reduces
macrophage-mediated inflammation, which contributes to insu-
lin resistance in obesity (Alhouayek et al., 2013). However, the
biochemical basis of these beneficial actions and the role of
ABHD6 in fuel homeostasis are unknown.
Although obesity is a major contributor to type 2 diabetes
(T2D), the current pharmacological approaches for treating
obesity and diabetes target different pathways. Several studies
showed altered expression of a specific gene, either by knockout
or overexpression, to offer protection against diet-induced
obesity (DIO), but none of these genes were shown to control
both insulin secretion and sensitivity directly (Dirkx et al., 2014;
Koh et al., 2013; Liew et al., 2010; Liu et al., 2014; Sumara
et al., 2009). It is desirable to identify a metabolic step/pathway
that can influence both insulin secretion and action in conjunc-
tion with additional beneficial effects on energy homeostasis,
such that a single target can be addressed for diabetes and
obesity.
Increased energy expenditure via fat oxidation and non-shiv-
ering thermogenesis by classical brown adipose tissue (BAT)
and by the stimulation of beige adipocytes likely provides an
avenue to alleviate the effects of obesity and prevent T2D (Wu
et al., 2013). Several recent reports indicate that augmented
BAT function and browning of white adipose tissue (WAT)s
(legend on next page)
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enhance glucose tolerance and insulin sensitivity and protect
from DIO and obesity-related diabetes (Cereijo et al., 2015; Pfei-
fer andHoffmann, 2015; Richard et al., 2010; Rosen andSpiegel-
man, 2014). Signaling via peroxisomal proliferator-activated
receptors (PPAR) is important for beige adipocyte formation
(Wu et al., 2012) and the stimulation of BAT (Rosen and Spiegel-
man, 2014). PPARa plays a role in maintaining brown adipocyte
phenotype and in WAT browning (Hondares et al., 2011b;
Roberts et al., 2014). Among the endogenous mediators of
BAT activation andWAT browning, besides catecholamines, trii-
dothyronine, FGF21, bone morphogenic proteins (Bartelt and
Heeren, 2014), and adenosine (Gnad et al., 2014), certain lipids
like prostaglandins and alkyl-ether lipids also play a role by
increasing PGC-1a levels or via PPARg activation (Bartelt and
Heeren, 2014). Recent studies suggest that certain lipolytic
products may activate PPARs (Badin et al., 2012; Haemmerle
et al., 2011; Mottillo et al., 2012) and thus may contribute to
adipose browning and BAT activation.
Our earlier study (Zhao et al., 2014) identified a signaling role
for MAG and ABHD6 in b cell insulin secretion and glucose
homeostasis, but the importance of MAG and ABHD6 in overall
energy homeostasis was not addressed. ABHD6 was shown to
be induced by high-fat diet in liver but not in BAT (Thomas et al.,
2013), indicating this protein to be nutritionally regulated at
least in liver. In order to understand the role of ABHD6 and
monoacylglycerol in energy homeostasis, we studied whole-
body ABHD6-KO mice and DIO mice treated with ABHD6-
directed antisense oligo (ASO) or an ABHD6 inhibitor. When
fed a HFD, ABHD6-KO mice show a unique phenotype that im-
plicates ABHD6 in obesity, metabolic syndrome, and diabetes.
ABHD6-KO mice display a modest reduction of appetite, are
protected from obesity, glucose intolerance, insulin resistance,
hyperinsulinemia, and hepatic steatosis, and also show
enhanced locomotor activity, BAT activity, and WAT browning.
The adipose browning effects could be recapitulated by treating
wild-type DIO mice with ABHD6 inhibitor or antisense oligonu-
cleotides (ASO) and appear to be, at least in part, intrinsic toFigure 1. Improved Glucose Tolerance, Insulin Sensitivity, Reduced Fo
Glucose Uptake in ABHD6-KO Mice on High-Fat Diet
Male and female ABHD6-KO (homozygous), heterozygous (HZ), and wild-type (W
monitored. Oral glucose tolerance test (OGTT) was performed after 8 weeks, a
analyzed for glucose and insulin by ELISA. Insulin tolerance test (ITT) and hyperi
(A) Glycemia during OGTT on male WT, HZ, and KO mice (n = 9). Inset depicts a
(B) Insulinemia during OGTT in male mice. Inset, area under the curve.
(C) Glycemia during ITT on male mice (n = 6). Inset depicts area above the curve
(D) Glycemia during OGTT on female mice (n = 8). Inset depicts area under the c
(E) Corresponding plasma insulin levels for female mice.
(F) Blood glucose levels during ITT on female mice (n = 8). Inset depicts area abo
(G) Blood glucose levels during HIEC on male WT (n = 8), HZ (n = 9), and KO (n =
(H) Glucose infusion rate (GIR) during HIEC on male mice.
(I) Body weight gain of male WT, HZ, and KO mice (n = 9).
(J) Cumulative food intake of male mice over 7 weeks.
(K) Body weight gain in female mice (n = 9).
(L) Cumulative food intake in female mice over 7 weeks.
(M–P) Glucose uptake in muscle and fat tissue. Soleus muscle and visceral fat fro
measuring glucose uptake with [3H]-2-deoxy-glucose (2DG), in the absence or pre
uptake in visceral fat of male mice. (N) Glucose uptake in soleus muscle of male
soleus muscle of female mice.
*p < 0.05 versus WT. *p < 0.05; **p < 0.01 versus WT. See also Table S1 and Fig
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PPARa and PPARg activation.
RESULTS
ABHD6-KO Mice on a High-Fat Diet Show Reduced
Weight Gain and Improved Glucose Tolerance and
Insulin Sensitivity
Bothmale and femaleABHD6-KOmice fed 60%HFD for 8weeks
showed improved glucose tolerance but much lower insulinemia
during OGTT and also enhanced insulin sensitivity during insulin
tolerance test (ITT) (Figures 1A–1F). Heterozygous mice showed
an intermediate response, more notably for insulinemia. The low
insulinemia response in KO mice during OGTT (Figures 1B and
1E) was suggestive of enhanced insulin sensitivity, which was
confirmed by ITT (Figures 1C and 1F) and also by hyperinsuline-
mic-euglycemic clamp (Figures 1G and 1H). Glucose infusion
rate (index of insulin sensitivity) in HFD-fed male KO mice was
higher as compared to WT mice, with heterozygous mice
showing intermediate effect (Figure 1H). During HFD feeding,
both male and female ABHD6-KO mice showed less body
weight gain (Figures 1I and 1K) and reduced cumulative food
intake (Figures 1J and 1L). The decrease in body weight gain
was more pronounced in female KO mice (30% at week 8) as
compared to male KO mice (12% at week 8), whereas the
reduction in cumulative food intake (7% at weeks 6–8) in
both sexes was modest, compared to WT mice.
We previously showed that male ABHD6-KO mice on pure
C57Bl6/N genetic background when placed on chow diet
show normal body weight gain and food intake over a 3- to 24-
week period and unaltered insulin sensitivity in 26-week-old
male ABHD6-KO mice (Zhao et al., 2014). We also found that
6-week-old ABHD6-KO male mice on chow diet showed no dif-
ferences in their glucose tolerance compared to wild-type (WT)
mice during oral glucose tolerance test (OGTT), despite
increased insulin secretion (data not shown) and unaltered insu-
lin sensitivity as revealed by insulin tolerance test (ITT). Unlikeod Intake, and Body Weight Gain, and Elevated Muscle and Adipose
T) mice were maintained on HFD, and food intake and body weight gain were
fter a 6-hr food deprivation. Tail blood was collected at indicated times and
nsulinemic euglycemic clamp (HIEC) were performed after 10 weeks on HFD.
rea under the curve (AUC) for glycemia.
(AAC).
urve.
ve the curve for insulinemia.
10) mice.
m ABHD6-KO and WT mice fed HFD for 12 weeks were removed and used for
sence of insulin (100 nM), as detailed in Experimental Procedures. (M) Glucose
mice. (O) Glucose uptake in visceral fat of female mice. (P) Glucose uptake in
ure S1.
s
(legend on next page)
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male KO mice, female ABHD6-KO mice on chow diet showed
slightly reduced body weight gain over 3–24 weeks of age and
cumulative food intake over 5–16 weeks of age and displayed
better glucose tolerance than WT mice but with reduced insulin
secretion during OGTT, indicating that female KOmice are more
insulin sensitive, which was confirmed by ITT (data not shown).
Overall, female ABHD6-KO mice show a more pronounced
phenotype than the males on chow diet.
Ex vivo analysis indicated that visceral fat and soleus muscle
from ABHD6-KO mice show enhanced glucose uptake under
basal and insulin-stimulated conditions and that insulin action
per se is not enhanced (Figures 1M–1P). These effects were
more pronounced in female mice (Figures 1O and 1P). Thus,
ABHD6 deficiency is associated with enhanced insulin indepen-
dent glucose uptake by muscle and adipose tissues that likely
contributes to improved glucose disposal in the KO mice.
Reduced Fat Mass and Liver Steatosis in
ABHD6-KO Mice
Echo-MRI of ABHD6-KO mice revealed no difference in lean
mass (Figures S1A and S1E). Fat mass (Figures S1B and S1F)
was markedly decreased in female KO mice and modestly in
males. Liver weight showed significant reduction in the KO
mice as compared to WT mice in both males (Figure S1C) and
females (Figure S1G), and this may be related to decreased fat
content, as noticed in liver histology, showing more fat accumu-
lation in the WT than KO mice (Figure S1I). In fact, liver TG con-
tent was decreased in both female andmale KOmice on HFD, as
compared to WT mice (Figures S1J and S1K). There was no
change in visceral fat weight in male KO mice (Figure S1D) while
in female KO mice this was reduced by 40% (Figure S1H) and
was visually evident (Figure S1L).
Blood Chemistry and Additional Parameters of
ABHD6-KO Mice
ABHD6-KO mice on HFD showed reduced glycemia and insuli-
nemia. On normal diet, neither glycemia nor insulinemia was
different between KO andWTmice (Table S1). There were no dif-
ferences in plasma glycerol, triglyceride, free fatty acids, or free
and total cholesterol levels in chow or HFD-fed KO versus WT
mice (Table S1). Rectal temperature of female KO mice was
slightly (not significant) higher than WT mice, suggestive of
elevated energy expenditure (see below). The growth character-
istics of ABHD6-KO mice were not altered as indicated by their
body and tail length in comparison to WT mice. Fur appearance
was also not different (Figure S1L). We measured various adipo-Figure 2. Increased Energy Expenditure and Locomotor Activity in Hig
Male and female ABHD6-KO, HZ, and WT (n = 10) mice were fed HFD for 6 week
room temperature for 3 days. After acclimatization for the first 2 days, volume of O
and, based on these parameters, respiration exchange ratio (RER) and energy exp
also made with HFD-fed male ABHD6-KO andWTmice under thermoneutral (30
third day.
(A) Volume O2.
(B) Volume CO2 (expressed as liters/kg body weight/hr).
(C) RER.
(D) Energy expenditure (expressed as kcal/kg metabolic mass/hr).
(E) Locomotor activity (arbitrary units). Metabolic mass was calculated as lean m
*p < 0.05; ***p < 0.001 versus WT. See also Figure S2.
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HFD mice (Figures S1M and S1N) and only six of them showed
significant changes (Figure S1M). Fibroblast growth factors
(FGF21 and FGF), which are implicated in protection from
obesity-mediated complications (Kharitonenkov and Adams,
2014; Owen et al., 2014), were elevated in the plasma of KO
mice, whereas proteins related to insulin resistance including
ICAM-1, IGFBP-1, and resistin were decreased. RAGE, indica-
tive of inflammation, was also reduced.
Elevated Respiration, Energy Expenditure, and
Locomotor Activity in ABHD6-KO Mice
ABHD6-KO mice were acclimatized for 48 hr in metabolic cages
either at room temperature or at 30C (thermoneutral condi-
tions), and measurements were made on the subsequent 24-hr
period (third day). Respiratory measurements indicated elevated
VO2 during light and dark phases (data not shown) and during the
last 24-hr period (Figure 2A) both in male and female mice, at
both room temperature and 30C. VCO2 and respiratory ex-
change ratio (RER) were not affected (Figures 2B and 2C). En-
ergy expenditure as a function of metabolic mass (lean mass +
0.2 3 fat mass) was higher in both female and male ABHD6-
KO mice, in both the dark and light phases, last 24 hr, and at
both temperatures (Figures S2A and 2D).
ABHD6-KO mice show increased locomotor activity over a
24-hr time period (Figure 2E) and during dark phase, and this in-
crease was more marked in females (Figure S2B). In order to
determine whether increased locomotor activity is due to
changes in anxiety, mice were tested in the elevated-plus
maze and open-field tests. Further, we used the Porsolt forced
swim test to verify whether ABHD6-KO affects depressive-like
behavior, a secondary effect sometimes associated with appe-
tite suppression. No differences were observed between WT
and KO mice for any of these parameters (Figures S2C–S2E),
suggesting that the enhanced locomotor activity of KO mice is
due to voluntary exercise.
Enhanced BAT Function and WAT ‘‘Browning’’ in
ABHD6-KO Mice
As ABHD6-KO mice on HFD show enhanced energy expendi-
ture, we examined whether BAT function is elevated in these
mice and whether white adipose undergoes ‘‘browning.’’ We
measured in female ABHD6-KOmice thermogenic gene expres-
sion in BAT and genes associated with adipose browning in
visceral and inguinal WAT. UCP1, PGC1a, PRDM16, PPARa,
and CD36mRNA levels (Figures 3A–3E) were elevated in visceralh-Fat-Diet-Fed ABHD6-KO Mice
s, and at the end of feeding period the mice were placed in metabolic cages at
2, CO2 as well as locomotor activity measurements were made on the third day,
enditure (EE) were calculated. In parallel, metabolic cage measurements were
C) conditions (n = 7). Results shown were calculated for the 24-hr period on the
ass + 0.2 3 fat mass for each mouse.
s
Figure 3. Increased Expression of UCP1 and Other Adipose Browning-Related Genes, Cold-Induced Thermogenesis, and Brown Adipose
Fatty Acid Oxidation in HFD-Fed ABHD6-KO Mice
(A–E) Female ABHD6-KO (n = 7) andWT (n = 7)mice fedHFD for 10weekswere sacrificed, and visceral, inguinal, and brown fat tissueswere removed for analysis.
Total RNA was extracted, and the expression of various browning marker genes was assessed by RT-PCR. All gene expressions are normalized to 18S RNA
expression.
(legend continued on next page)
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and inguinal WAT and in BAT from female KO mice. Expression
of other browning-related genes (TBX1, CD137, TMEM26,
Cox8b, Cox7a1, CIDEA) (data not shown) showed moderate or
no change. Expression of PPARa, which controls UCP1 tran-
scription (Xue et al., 2005), was elevated in WAT and BAT (Fig-
ure 3D), but no significant changes were seen in PPARb or
PPARg (data not shown). PPARa target genes CD36 (Figure 3E)
and CPT-1 (data not shown) showed increased expression in the
KO mice. Histology revealed smaller adipocytes in the visceral
and inguinal adipose tissues and smaller adipocytes with much
less lipid deposits in the BAT of the ABHD6-KOmice (Figure 3F).
UCP1 protein staining was higher in visceral, inguinal, and brown
adipose tissues of KO mice (Figure 3G). UCP1 protein levels,
quantified from western blots, increased in KO mouse WAT
and BAT (Figures S3A–S3C). Cold (4C)-induced thermogenesis
for 3 hr revealed higher ability of the KO mice to maintain their
body temperature (Figure 3H), and UCP1 protein levels in these
cold-exposed WT and ABHD6-KO mice also showed significant
increase (Figures S3D and S3E). Similar gene expression
changes were noticed in WAT and BAT from ABHD6-KO mice
after 3-day acclimatization at 30C, except that PPARg induction
was more apparent (Figures S4A–S4H). The elevated UCP1 pro-
tein levels seen in both WAT and BAT of ABHD6-KO mice at
room temperature conditions were also found to be increased
under thermoneutral conditions (Figures S4B and S4C). BAT
from KO mice showed nearly 2-fold increase in b-oxidation (Fig-
ure 3I). Thus, there is increased thermogenic program and func-
tion in BAT and induction of browning-related genes in visceral
and subcutaneous adipose tissues of the ABHD6-KO mice.
Pharmacological Inhibition or ASO Knockdown of
ABHD6 Triggers Adipose Browning
Administration of ABHD6 inhibitor WWL70 or ABHD6-ASO was
shown to protect mice from DIO (Thomas et al., 2013). In order
to examine whether pharmacological inhibition of ABHD6 in-
duces adipose browning as seen in ABHD6-KO mice, C57Bl6N
mice on HFD (45% calories from fat; 8 weeks) were treated daily
with WWL70. Administration of WWL70 elevated UCP1 (Fig-
ure 4A) and induced other browning-related genes (Figures
4B–4D) in the visceral adipose. Expression of Cidea and
Cox7a1 showed marginal increase, whereas UCP2, PPARa,
and PPARg were unaltered in WWL70-treated mice (data not
shown).
ABHD6-ASO-treated mice on 45% HFD showed markedly
reduced ABHD6 expression in visceral adipose in association
with induction of UCP1, PRDM16, PPARa, and PPARg (Figures
4E–4I). Expression of Cox7a1, Elovl3, TBX1, and TMEM26
were also elevated in the ABHD6-ASO-treated mice, whereas
Cidea expression did not change (Figures 4J–4N). Similar to
ABHD6-KO mice, ASO-treated mice maintained their body tem-
perature in cold better than controls and the area above the
curve indicated significantly lower decline in body temperature(F and G) Histological (H&E staining) and immunochemical (for UCP1 expression
(H) Another batch of HFD-fed ABHD6-KO and WT mice were placed in cold room
rectal temperature.
(I) Fatty acid oxidation using [1-14C]-palmitate measured in brown adipose tissue
*p < 0.05; **p < 0.01 versus WT. See also Figures S3 and S4.
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tion or knockdown of ABHD6 causes WAT browning as seen in
the KO mice.
ASO Knockdown of ABHD6 in Differentiated 3T3-L1
Cells Induces Browning-Related Gene Expression
We further examined whether the adipose browning-inducing ef-
fects of ABHD6-ASO are cell autonomous using 3T3-L1 preadi-
pocytes after differentiation. Treatment of fully differentiated
3T3-L1 cells with ABHD6-ASO for 24 hr led to decreased
mRNA levels of ABHD6 and elevated expression of UCP1,
PGC1a, PRDM16, PPARa, and TMEM26 (Figures 4P–4V). These
results are consistent with the view that ABHD6 ASO knockdown
effects on browning are cell autonomous.
ABHD6 Inhibition and 1-MAG Cause Adipose Browning
via PPARa and PPARg in a Cell-Autonomous Manner
To gain insight into the mechanism by which ABHD6 inhibition
causes WAT browning, we first verified whether 1-MAG hydro-
lase activity is lowered in the adipose tissues of ABHD6-KO
mice, which also contain the classical MAG lipase (Taschler
et al., 2011). Total 1-MAG hydrolase activity in extracts of
visceral and brown adipose tissues from the KO mice was
markedly decreased (Figure 5A) indicating that ABHD6 contribu-
tion to MAG hydrolysis in these adipose tissues is significant.
MAG hydrolase activity in inguinal adipose was not altered (Fig-
ure 5A). The decreased MAG hydrolase activity in WAT and BAT
was reflected in elevated 1-MAG species in these adipose tis-
sues (Figures 5B and 5C). Changes in 2-MAG levels weremodest
(data not shown), similar to our earlier report in ABHD6-KO
mouse islets (Zhao et al., 2014). Normalization of MAG levels
as a function of total tissue protein yielded similar pattern (data
not shown).
We examined whether the effects of ABHD6 suppression
are cell autonomous and intrinsic to adipocyte and whether
1-MAG acts as a signal for browning. Incubation of differentiated
3T3-L1 mouse adipocytes with WWL70, 1-oleoylglycerol, or
1-palmitoylglycerol increased expression of the browning
marker UCP1 and PPARa (Figure S5A). Similar changes were
noticed with WWL70 and 1-oleoylglycerol in differentiated hu-
man primary preadipocytes (Figure 5D). Addition of the PPARa
antagonist GW6471 completely abrogated the WWL70 and
1-oleoylglycerol-induced increases in UCP1 and PPARa expres-
sion (Figure 5D), suggesting that the browning changes seen in
WAT by ABHD6 suppression are mediated by1-MAG in a cell-
autonomous manner, at least in part via activation of PPARa.
WWL70 and 1-oleoylglycerol-stimulated respiration in 3T3-L1
adipocytes (Figures S5B–S5E) and human preadipocytes (Fig-
ures S5F–S5H), likely because of increased UCP1-mediated un-
coupled O2 consumption (Figures 5E, S5E, and S5F). Similar to
UCP1 expression, this increased O2 consumption was curtailed
by GW6471 (Figures 5E, S5B, and S5E).) examination on the adipose tissues.
(4C) for 3 hr, and cold-induced thermogenesis was evaluated by measuring
from mice fed a HFD.
s
Figure 4. Suppression of ABHD6 by WWL70 or Antisense-Oligonucleotide Increases Expression of Browning-Related Genes in White
Adipose Tissue, Differentiated 3T3-L1 Cells, and Cold-Induced Thermogenesis in HFD-Fed Mice
Wild-type C57Bl6N mice fed high-fat diet for 8 weeks were treated with WWL-70 (10 mg/kg/day, i.p.) or vehicle (n = 9 for each group) or ABHD6-ASO
(25 mg/kg/2 weeks) or control ASO (n = 9 for each group), during the feeding period. Cold-induced thermogenesis was assessed in ABHD6-ASO-treated mice at
the end of the 8-week period. After the feeding period, mice were sacrificed, and visceral fat was removed and processed for measuring the expression of UCP1
(legend continued on next page)
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Transactivation experiments revealed that 1-oleoylglycerol
and 1-palmitoylglycerol could activate PPARa-driven luciferase
gene expression, similar to PPARa agonist WY14643 (Figure 5F).
There was also significant transactivation of PPARg, but not
PPARb, by 1-MAG (Figure 5F). We verified the binding ability
and affinity of 1-MAG to PPARa and PPARg using PPAR-GAL4
binding assay, where the ligand binding domain of PPAR is fused
with GAL4 DNA binding domain and the expression of a reporter
gene is followed. Results showed that while the synthetic ligands
WY14643 and rosiglitazone showed high affinity to bind and acti-
vate PPARa and PPARg as expected (Figures S6A and S6D),
both 1-OG and 1-PG were also able to bind and activate these
PPARswith an EC50 of 10–19 mM,which is within their physiolog-
ical range of intracellular concentrations (Figures S6B, S6C, S6E,
and S6F). Finally, preadipocytes from ABHD6-KO mice ex-
pressed high levels of UCP1 and PPARa after differentiation as
compared to WT preadipocytes, an effect that was abrogated
by PPARa antagonist GW6471 (Figure 5G).
We further examined the contribution of PPARg to 1-MAG-
mediated browning. PPARg antagonist T0070907 led to sup-
pression of WWL70 or 1-oleoylglycerol-mediated increase in
the expression of UCP1 and other browning-related genes in hu-
man differentiated preadipocytes (Figure 5H). Overall, the data
support the view that 1-MAG mediates the adipocyte browning
induced by ABHD6 suppression in a cell-autonomous manner,
probably involving PPARa and PPARg activation.
Pair Feeding Does Not Prevent ABHD6-KO-Mediated
Protection from HFD-Induced Obesity, Glucose
Intolerance, and Insulin Resistance
Since ABHD6-KO mice on HFD exhibited slightly reduced food
intake, we verified whether this could explain the observed
effects on body weight gain, glucose tolerance, and insulin
sensitivity. After ABHD6-KO and WT mice were pair fed for
2 weeks, body weight gain was still lower in ABHD6-KO mice
(Figures 6A and 6B). Similarly, OGTT revealed improved glucose
tolerance and ITT showed better insulin sensitivity (Figures 6C–
6E) in the ABHD6-KO mice compared to the pair-fed WT mice.
The increased UCP1 protein content seen in WAT and BAT of
ad libitum HFD-fed ABHD6-KO mice was also noticeable in
pair-fed mice (Figures 6F–6I), suggesting that the beneficial
changes in glucose/insulin homeostasis seen in the KO mice
cannot be fully accounted for by changes in food intake.
PPARa Antagonism Counteracts Adipose Browning,
Thermogenic Program, andBeneficialMetabolic Effects
in ABHD6-KO Mice
Treatment of HFD-fed ABHD6-KO male mice with the PPARa
antagonist GW6471 slightly elevated their body weight gain (Fig-and browning-related genes normalized to 18S RNA. In order to assess the effect
differentiation were treated with control- or ABHD6-ASO for 24 hr. Then, the cell
(A–D) Browning-related gene expression in visceral adipose from WWL70-treate
(E–N) Browning-related gene expression in visceral adipose from control-ASO an
PPARg; (J) Cidea; (K) Cox7a1; (L) ELOVL3; (M) TBX1; and (N) TMEM26.
(O) Cold-induced thermogenesis in ABHD6-ASO-treated and control mice and th
(P–V) Gene expression in 3T3-L1 cells treated with control- or ABHD6-ASO. (P)
TMEM26. *p < 0.05; **p < 0.01; ***p < 0.001, compared to corresponding contro
2880 Cell Reports 14, 2872–2888, March 29, 2016 ª2016 The Authorure 7A), without altering food intake (Figure 7B). Even though gly-
cemia during OGTT was not changed (Figure 7C), insulinemia
showed a tendency to increase (Figure 7D) revealing lower insu-
lin sensitivity, and this was confirmed in ITT (Figure 7E). PPARa
antagonism lowered oxygen consumption and VCO2 in the
ABHD6-KO mice, without change in RER (Figures S7A–S7C).
The elevated energy expenditure in KO mice, measured at
30C, was reduced by GW6471 treatment (Figure 7F). This
decreased energy expenditure was associated with curtailed
expression of UCP1 (Figure 7G) and other browning-related
genes in BAT and WAT (Figures S7E–S7G), indicating that in
ABHD6-KO mice PPARa mediates adipose browning and ther-
mogenic reprogramming at least partially. Interestingly, the
increased locomotor activity seen in ABHD6-KO mice was also
curtailed by PPARa antagonism (Figure S7D). The elevated
b-oxidation in BAT of ABHD6-KO mice was also normalized to
WT levels by PPARa antagonist treatment (Figure S7H).
DISCUSSION
We previously demonstrated the regulatory role of ABHD6 and
1-saturated monoacylglycerol in insulin secretion by pancreatic
b cells and identified Munc13-1 as the intracellular receptor for
MAG-induced exocytosis (Zhao et al., 2014, 2015). The present
results indicate roles for ABHD6 in whole-body energy homeo-
stasis that are of interest for metabolic disorders. When fed
HFD the ABHD6 KO mice show (1) reduced body weight gain;
(2) protection from hepatic steatosis; (3) a modest lowering of
food intake; (4) improved glucose tolerance; (5) increased insulin
sensitivity and protection from hyperinsulinemia; (6) enhanced
insulin-independent glucose uptake in adipose and muscle;
(7) increased locomotor activity, females beingmore responsive;
(8) elevated energy expenditure; (9) augmented fatty acid oxida-
tion in BAT; (10) increased cold-induced thermogenesis;
(11) browning of WAT; and (12) increased plasma FGF21, which
antagonizes metabolic-syndrome-related defects and activates
BAT and beige adipocytes (Hondares et al., 2011a; Owen
et al., 2014). Heterozygous mice, partially deficient in ABHD6,
showed an intermediate phenotype between WT and KO mice
for many parameters, revealing a gene dosage effect. Also
several of these effects, in particular, adipose browning and
cold-induced thermogenesis, were replicated in vivo by the
ABHD6 inhibitor WWL70 and by ABHD6-ASO. Thus, the results
demonstrate that ABHD6 is a key player in the control of energy
homeostasis and in the regulation of BAT function and white
adipose browning. Recently, it has been observed that ASO
directed against ABHD6 causes elevated energy expenditure
and protects male mice against HFD-induced obesity, hepatic
steatosis, and systemic insulin resistance, but the underlyingof ABHD6 suppression by ASO in fully differentiated 3T3-L1 cells, the cells after
s were harvested for gene expression analysis by RT-PCR.
d and control mice. (A) UCP1, (B) PRDM16, (C) Tmem26, and (D) TBX1.
d ABHD6-ASO-treated mice: (E) ABHD6; (F) UCP1; (G) PRDM16; (H) PPARa; (I)
e area above the curve for temperature curves.
ABHD6; (Q) UCP1; (R) PGC1a; (S) PRDM16; (T) PPARa; (U) PPARg; and (V)
ls; n = 10 for each group.
s
Figure 5. Accumulation of 1-MAG in ABHD6-KO Mouse Adipose Tissues and PPARa and PPARg Dependence of Elevated Browning Gene
Expression by 1-MAG and WWL70 in Human Adipocytes or in ABHD6-KO Mouse Adipocytes
(A) MAG hydrolase activity in visceral, inguinal, and brown adipose tissues from ABHD6 WT and KO mice. Adipose tissues were employed for assaying MAG
hydrolysis activity using 1-S-arachidonoylglycerol. *p < 0.05 versus WT (n = 7, each).
(B and C) Visceral and brown adipose tissues were processed for MAG species analysis. (B) Increased levels of long-chain 1-MAG species in visceral adipose
isolated from HFD-fed female ABHD6-KO mice. *p < 0.05 versus WT mice (n = 7, each). (C) Increased levels of long-chain 1-MAG species in brown adipose
isolated from HFD-fed female ABHD6-KO mice (n = 7, each). *p < 0.05 versus WT.
(legend continued on next page)
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mechanism was not known (Thomas et al., 2013). The present
data provide that ABHD6-ASO induces WAT browning and
BAT activation, which contribute to the protective effect seen
in HFD mice. This comprehensive study of both males and
female mice on normal or high-fat diet considerably extends
our understanding of the role of ABHD6 and lipolysis-derived
1-MAG signaling in fuel homeostasis.
The mechanism whereby ABHD6 suppression exerts benefi-
ciarymetabolic effects is likelymultifactorial. The slight reduction
in food intake alone cannot quantitatively explain all metabolic
improvements. Thus, food intake was similarly reduced by
8% in male and female mice, yet the phenotype in females
for glucose tolerance, body weight gain, fat mass, and insulin
sensitivity was more pronounced. In addition, the protective ef-
fects of ABHD6-KO persist in the context of pair feeding, indi-
cating that the lower food intake is not primarily responsible for
the improved metabolic outcomes observed in ABHD6-KO
mice. The underlying causes for the modestly lowered food
intake in the KO mice are not clear. Central ABHD6 involvement
is a possibility; however, a decrease in ABHD6 activity is ex-
pected to increase the endocannabinoid 2-arachidonoylglycerol
that in fact enhances appetite (Di Marzo and Matias, 2005),
which is not the case in the KO mice. Also, ABHD6 ASO, which
does not lower brain ABHD6 levels, caused similar metabolic ef-
fects (Thomas et al., 2013); central involvement cannot explain
the reduced appetite and metabolic effects in the KO mice.
Also, recently it has been shown that ABHD6 inhibition in vivo
by WWL70 had no effect on brain 2-AG levels (Alhouayek
et al., 2013), indicating that ABHD6 suppression mediates its ef-
fects largely independent of central involvement. At least part of
the beneficiary effects of ABHD6-KO on glycemia could be due
to the enhanced insulin-independent glucose uptake both in
skeletal muscle and adipose tissues, and this, in turn, could
contribute to decreased body demand for insulin and thus to
reduced hyperinsulinemia that drives obesity (Wiernsperger,
2005a, 2005b).
However, an important contributor to the beneficiary effect
of ABHD6 deletion is likely enhanced BAT function and also
WAT browning. Thus, energy expenditure was increased in
KO mice during the light phase when the animals did not
show any difference in locomotor activity. Furthermore, energy(D) PPARa dependence of elevated browning gene (UCP1, PGC1a, PRDM16, and
differentiated human adipocytes were incubated overnight with either DMSO veh
absence of PPARa antagonist 1 mM GW6471, and the cells were collected for m
control (DMSO); #p < 0.05 versus GW6471.
(E) Stimulation of uncoupled oxygen consumption rate (OCR) in differentiated hum
antagonist GW6471 (n = 5). *p < 0.05 versus DMSO control; #p < 0.05 versus GW
(F) Transactivation of PPARa and PPARg by 1-MAG. PPAR transactivation assay
or PPARg, using dual luciferase PPRE reporter assay.WY14643, GW501516, and
and PPARg, respectively (n = 6). *p < 0.05, **p < 0.01, ***p < 0.001 versus DMSO
(G) PPARa antagonist GW6471 suppresses the expression of browning-related g
from pre-adipocytes isolated from chow-diet-fed ABHD6-KO andWTmice. C, DM
versus KO-DMSO (n = 5).
(H) PPARg dependence of elevated browning gene (UCP1, PGC1a, PPARa, and P
adipocytes were treated as in (D) overnight with WWL70 or 1-oleoyglycerol in th
pocytes were harvested, and mRNA expression of browning-related genes was
*p < 0.05; **p < 0.01; ***p < 0.001 versus control (C); #p < 0.05; ###p < 0.001 versu
See also Figure S5.
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indicating that these effects are not because of room-tempera-
ture-mediated stimulation of BAT and also not due to any skin
or fur defects as pointed out recently (Nedergaard and Cannon,
2014). In addition, cold-induced thermogenesis was enhanced
in both ABHD6-KO and ABHD6-ASO-treated mice. It is also
important to point out that, while subcutaneous adipose was
considered to be the prime target of browning in other mouse
models, we find that predominant changes in browning-related
gene expression are noticeable in visceral WAT in ABHD6-KO
mice.
Little is known about the biochemical basis of WAT browning.
Several transcriptional regulators including PPARs and co-acti-
vators PRDM16 and PGC1a are known to be involved in the
conversion of WAT to brite adipose (Richard et al., 2010; Rosen
and Spiegelman, 2014). However, whether metabolic pathways
or signals play a role in this process is unknown. The results
support the view that 1-MAG signaling can drive intrinsic and
cell-autonomous adipose browning in part via PPARa and
PPARg activation and that ABHD6 regulates adipose browning
by controlling the signal competent 1-MAG levels. The evidence
is as follows: (1) various 1-MAG species are increased in
visceral adipose of ABHD6-KO mice; (2) 1-MAG, WWL70, and
ABHD6-ASO induce UCP1 and PPARa in differentiated 3T3L1
preadipocytes and human preadipocytes; (3) PPARa and
PPARg antagonists abrogate UCP1 induction by 1-MAG and
ABHD6 inhibition in adipocytes; (4) UCP1 expression is dramat-
ically induced during differentiation of preadipocytes from
ABHD6-KO WAT, and this is completely abolished by PPARa
antagonism; (5) 1-MAG can activate PPARa and PPARg directly
by binding to the ligand binding domain of these transcription
factors; (6) PPARa and PPARg target genes are induced in
ABHD6-KO WAT; (7) 1-MAG and WWL70 increase uncoupled
respiration in 3T3L1 preadipocytes and human adipocytes,
and this is blocked by a PPARa antagonist; (8) PPARa antago-
nist treatment of ABHD6-KO mice prevents the browning phe-
nomenon and associated metabolic changes; and (9) treatment
of mice with ABHD6-ASO or WWL70 induces WAT browning
similar to ABHD6-KO. However, considering that PPARs are
necessary for UCP1 expression per se, and that the PPARa
antagonist also decreased UCP1 expression in the WAT andPPARa) expression by 1-oleoylglycerol or WWL70 in human adipocytes. Fully
icle (control, C), 10 mMWWL70 (W), or 100 mM 1-OG (OG), in the presence and
RNA analysis. Results were normalized to 18S RNA (n = 5). *p < 0.05 versus
an adipocytes by 1-OG and WWL70, and this increase is curtailed by PPARa
6471. For further details, see Figure S4E.
was done in 293T cells, transfected with plasmids expressing PPARa, PPARb,
pioglitazone were used as positive controls for the activation of PPARa, PPARb,
.
enes UCP1, PGC1a, PRDM16, and PPARa in adipocytes differentiated ex vivo
SO control; G, GW6471 treated. ***p < 0.001 versus WT-DMSO; ###p < 0.001
PARg) expression by 1-oleoylglycerol or WWL70 in human adipocytes. Human
e absence or presence of 1 mM PPARg antagonist T0070907. Then, the adi-
assessed by RT-PCR. Gene expressions were normalized to 18S RNA.
s corresponding WWL70 (W) or 1-OG (OG) without T0070907 treatment (n = 5).
s
Figure 6. Pair-Fed ABHD6-KO Mice on HFD
Also Show Reduced Body Weight, Improved
Glucose Tolerance, and Insulin Sensitivity
Male ABHD6-KO and WT mice (6 weeks old) were
pair fed HFD. Daily body weight gain was moni-
tored, and OGTT and ITT were performed at the
end of the feeding period. Then, the mice were
sacrificed, and visceral and brown fat tissues were
isolated for western blot analysis of UCP1.
(A) Body weight.
(B) Daily food intake of KO mice; the same amount
of food is given to pair-fed WT mice.
(C) Glycemia during OGTT. Inset depicts AUC.
(D) Insulinemia during OGTT. Inset depicts AUC.
(E) ITT. Results of ITT were calculated as per-
centage of basal (0 min) glycemia.
(F and G) UCP1 protein expression in WAT (F) and
UCP1 protein expression in BAT (G).
(H and I) Quantification of UCP1 protein expression
in western blots of WAT (F) and BAT (G).
*p < 0.05; **p < 0.01 versus WT.BAT of WT mice, additional PPAR-independent mechanisms for
1-MAG-mediated adipose browning and BAT activation are
possible.
ABHD6 and 1-MAG also appear to play a role in BAT function,
which is important considering that the thermogenic contribution
of classical BAT is likely predominant, even under conditions of
‘‘WAT browning’’ (Shabalina et al., 2013). Thus, ABHD6-KO
mice showed elevated levels of various 1-MAG species in BAT,
whereas 2-MAG did not rise significantly. BAT of the KO mice
showed higher fat oxidation and induction of many of the BAT
marker genes including PRDM16, PPARa, CD36, PGC1a, and
CIDEA. Also, UCP1 level was markedly increased in BAT of the
KO mice in association with better cold tolerance despite being
leaner. Similar to WAT browning, 1-MAG appears to activate
BAT function at least in part through PPARa; however, other
mechanisms are possible. This inference is supported by the
counteracting effect of PPARa antagonist on UCP1 induction
in ABHD6-KO mice.Cell Reports 14, 2872–2888The phenotype of male and female
ABHD6-KO mice was qualitatively similar
even though it was quantitatively more
marked in females. The reason for this is
uncertain, but estrogens are well known
to be protective against metabolic syn-
drome and diabetes (Mauvais-Jarvis
et al., 2013; Zhu et al., 2014). Also, BAT
in female mice is more efficient in its mito-
chondrial organization (Nadal-Casellas
et al., 2013; Nookaew et al., 2013), which
may also contribute to their increased
responsiveness to ABHD6 deletion.
Mechanism underlying the elevated lo-
comotor function seen in the ABHD6-KO
mice is not clear. Since there is no associ-
ated stress or anxiety in the ABHD6-KO
mice, and, as the elevated locomotor ac-
tivity is seen mostly during dark phase,when the rodents are more active, it can be inferred that
ABHD6 suppression promotes voluntary exercise. The effects
on locomotor function may also be dependent on PPAR activa-
tion, as these effects could be suppressed by PPARa antagonist.
Lipolytic products are important physiological activators of
both PPARa and PPARg (Badin et al., 2012; Haemmerle et al.,
2011; Mottillo et al., 2012). Several reports indicate the role of
PPARg in WAT browning and BAT function (Ohno et al., 2012;
Spiegelman, 2013). Indeed, we noticed that 1-MAG can also
activate PPARg in addition to PPARa, but not PPARb/d. Inas-
much as PPARg antagonist could lower the effectiveness of
WWL70 and 1-oleoylglycerol in inducing browning-related
gene expression in differentiated human preadipocytes, it ap-
pears that PPARg also plays a role in controlling ABHD6/1-
MAG-mediated adipose browning, besides other mechanisms.
The possibility that certain centrally mediated effects play a
role in the elevated locomotor activity and in adipose browning
and BAT activation cannot be eliminated entirely in the, March 29, 2016 ª2016 The Authors 2883
(legend on next page)
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ABHD6-KO mice, even though the results from ABHD6-ASO-
treated mice do not support this mechanism as ASO does not
cross the blood-brain barrier and does not reduce ABHD6
expression in brain (Thomas et al., 2013).
Collectively, our results demonstrate that ABHD6 regulates
fuel homeostasis, WAT browning, and BAT function. The mech-
anism of adipose browning appears to involve 1-monoacylgly-
cerol acting as an intrinsic cell-autonomous signal that causes
it beneficial effects in part via PPARa and PPARg activation in
adipose tissues. ABHD6 inhibition may provide a therapeutic
approach for both lean and obese T2D. Thus, it was reported
earlier that ABHD6 inhibition in the low-dose streptozotocin
lean model of T2D restores normal glucose tolerance via
enhanced insulin secretion (Zhao et al., 2014). Here, we show
in obese mice with hyperglycemia and marked glucose intoler-
ance that ABHD6 deficiency reduces body weight gain and im-
proves glucose homeostasis and insulin action together with
mild reduction in appetite and enhanced locomotor activity. Tar-
geting ABHD6 offers a distinct way to develop both anti-obesity
and T2D drugs.
EXPERIMENTAL PROCEDURES
Generation and Maintenance of Whole-Body ABHD6-KO Mice
All procedures involving animal studies were approved by the Institutional
Committee for the Protection of Animals. Whole-body ABHD6-KO mice
were generated on pure C57Bl6N background (Zhao et al., 2014). The mice
were maintained individual cages on a standard chow diet (Harlan Teklad,
15% fat by energy) and 12-hr-dark/light cycle at 21C with free access to
water.
Metabolic Studies on High-Fat-Diet-Fed Mice
Male and female wild-type (WT), homozygous ABHD6-KO (KO), and heterozy-
gous (HZ) mice (5 weeks) were placed on chow or high-fat diet (HFD; 60% fat
by energy) for 8 weeks (Peyot et al., 2010). Body weight and food intake were
monitored each week. At the end of feeding regimen, mice were placed in
metabolic cages, for 3 days and O2 consumption (VO2), CO2 production
(VCO2), respiratory exchange ratio (RER), locomotor activity, and energy
expenditure by indirect calorimetry were monitored. Energy expenditure was
expressed as a function of metabolic mass (lean mass + 0.2 3 fat mass) as
suggested previously (Even and Nadkarni, 2012). Two days after CLAMS
studies, lean and fat mass were determined by echo MRI. Then oral glucose
tolerance test (OGTT) was performed.
Hyperinsulinemic Euglycemic Clamp, OGTT, and ITT
Male and femaleWT, ABHD6-KO, andHZmice on chowdiet or HFDwere used
for OGTT and ITT (Zhao et al., 2014). Hyperinsulinemic euglycemic clamp
(HIEC) was done on male mice fed HFD, and OGTT was performed on maleFigure 7. Reversal of ABHD6-KO-Mediated Effects on Obesity, Gluco
Tissue UCP1 Expression by PPARa Antagonist
Female ABHD6-KO and WT mice were fed HFD for 8 weeks without or with PPAR
weight gain and food intake were monitored, and, at the end of feeding-period e
performed. Then, the mice were sacrificed, and adipose tissues were isolated fo
(A) Body weight.
(B) Food intake.
(C) Glycemia during OGTT. Inset depicts area under the curve (AUC).
(D) Insulinemia during OGTT. Inset depicts AUC.
(E) ITT. Glycemia with time is shown as percentage of basal 0 min value.
(F) Energy expenditure under thermoneutrality (30C) conditions (expressed as k
(G) UCP1 expression in visceral, inguinal, and brown adipose tissues (n = 6, eac
*p < 0.05, **p < 0.01, ***p < 0.001 versus WT-Vehicle; #p < 0.05 versus KO-Vehi
Celland female mice (Zhao et al., 2014). Intraperitoneal insulin tolerance test
(IP-ITT) was performed under fed conditions. Insulin was administered intra-
peritoneally at a dose of 0.75 U/kg body weight (BW). Blood was collected
at different times, and glycemia was monitored.
Cold-Induced Thermogenesis
Female ABHD6-KO and WT mice, maintained on HFD for 12 weeks, were
placed in individual cages at 4C. Rectal temperature was monitored prior to
cold exposure and at indicated times during cold exposure for 3 hr.
PPARa Antagonist Treatment of Mice
Female ABHD6-KO and WT mice, kept on HFD for 8 weeks, were given
PPARa antagonist GW6471 once every 2 days (1 mg/kg BW) or vehicle,
intraperitoneally. Mice were then placed in metabolic cages at thermoneutral
condition (30C), and respiratory exchange ratio, energy expenditure, and lo-
comotor activity were recorded. Then, lean and fat mass of these mice were
measured followed by OGTT and ITT. Then, the mice were sacrificed, and
visceral, inguinal, and brown fat tissues were isolated for gene expression
analysis.
Behavior Tests
Tests for assessing anxiety (elevated plusmaze and open field) and depressive
behavior (forced swimming) were conducted on ABHD6-KO and WT mice
(Sharma and Fulton, 2013).
Treatment of High-Fat-Diet-Fed Mice with ABHD6 Inhibitor
Male mice (6–8 weeks old) were fed 45% fat diet for 8 weeks. Mice received
either WWL70 at 10 mg/kg BW/day intraperitoneally or vehicle (controls). After
8 weeks, mice were sacrificed, and visceral fat was processed for UCP1
immunohistochemistry and browning-related gene expression.
Treatment of High-Fat-Diet-Fed Mice with ABHD6 Antisense
Oligonucleotide
A 20-mer phosphorothioate antisense oligonucleotide (ASO) against ABHD6
was designed and supplied by ISIS Pharmaceuticals (Thomas et al., 2013).
Male mice (6–8 weeks old) were fed a 45% fat diet for 8 weeks. One group
of mice was injected with ABHD6-ASO biweekly (25 mg/kg BW), and another
group was given control ASO. After 8 weeks, cold-induced thermogenesis at
4C was assessed and the mice were sacrificed, and visceral fat was pro-
cessed for measuring browning-related gene expression.
Glucose Uptake and Fatty Acid Oxidation
Glucose uptake was measured using 0.1 mM [3H]-2-deoxyglucose (5 mCi;
PerkinElmer) in visceral fat and soleus muscle (Attane´ et al., 2011), and palmi-
tate oxidation was measured with 1 mM 1-14C]-palmitate (PerkinElmer) in
inguinal fat, visceral fat, brown fat, and soleus muscle (Attane´ et al., 2012), iso-
lated from ABHD6-KO and WT mice on HFD for 14 weeks.
PPAR Transactivation Assay
293T Cells were transfected with plasmids expressing PPARa, PPARb or
PPARg, PPAR response element-directed luciferase expression plasmidse Tolerance, Insulin Sensitivity, Energy Expenditure, and Adipose
a antagonist GW6471 treatment (1 mg/kg; once every 2 days, i.p.). Daily body
nergy expenditure, lean and fat mass were assessed, and OGTT and ITT were
r measuring browning-related gene expression.
cal/kg metabolic mass), during light and dark phases and complete 24 hr.
h group).
cle. See also Figure S5.
Reports 14, 2872–2888, March 29, 2016 ª2016 The Authors 2885
(PPRE X3-TK-luc) and Renilla luciferase control plasmid. The transfected cells
were starved overnight in DMEM without FBS and incubated in FBS-free
DMEM with 10 mM WWL70, 100 mM 1-palmitoylglycerol, 100 mM 1-oleoylgly-
cerol, 50 mM WY14643, 100 nM GW501516, 50 mM pioglitazone, or dimethyl-
sulfoxide vehicle for another 24 hr. Then, the cells were lysed and processed
for luciferase assay. PPRE-directed luciferase expression was normalized
with Renilla luciferase activity (internal control).
Analysis of Monoacylglycerol Species
Analysis of MAG species was as done previously (Zhao et al., 2014). Briefly,
total lipids were extracted from visceral and brown fat from ABHD6 WT and
KO mice. The extracted lipids were dissolved in 50 ml chloroform, and 1-
and 2-MAGs were separated on thin layer chromatography plates.
Monoacylglycerol Hydrolysis Activity
Adipose tissues from HFD-fed ABHD6-KO and WT mice were quickly washed
and homogenized in Krebs-Ringer bicarbonate hepes. Total MAG hydrolysis
activity was measured in the tissue homogenates using 5 mM 1-S-arachido-
noylthioglycerol and ThioGlo-1 (Covalent Associates) as fluorescent probe
(Zhao et al., 2014).
Effect of PPARa and PPARg Antagonists, In Vitro, on the Expression
of Genes Related to Adipose Browning
Differentiated 3T3-L1 cells (Kohanski et al., 1986) and human primary adipo-
cytes (Ahfeldt et al., 2012) and preadipocytes from ABHD6-KO and WT mice
were prepared (Liu et al., 2010) as described before. The differentiated adi-
pocytes were treated with 10 mM WWL70, 100 mM 1-oleoylglycerol in the
absence or presence of 1 mM PPARa antagonist GW6471 (Wang et al.,
2013), or 1 mM PPARg antagonist T0070907 (Lee et al., 2002) for 24 hr,
and then the cells were used for mRNA analysis of genes related to adipose
browning.
Oxygen Consumption Rates in Adipocytes
Differentiated mouse 3T3-L1 cells and human adipocytes were treated over-
night in DMEM medium with DMSO, 100 mM 1-oleoylglycerol, or 10 mM
WWL70, without and with 1 mM GW6471. Next day, the incubation medium
was replaced with unbuffered DMEM-based medium (Seahorse Bioscience)
with 25 mM glucose with or without various inhibitors. Cells were incubated
for 1 hr, and then the oxygen consumption rate was measured using XF
analyzer (Seahorse Bioscience).
Statistical Analysis
Statistical analysis was performed using one-way ANOVAwith Dunnett’s post-
test for multiple comparisons or two-way ANOVA with Bonferroni’s post-test
for multiple comparisons using GraphPad Prism. For browning gene expres-
sion results, comparisons were made by unpaired two-tailed Student’s
t test. Values are expressed as means ± SEM.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and one table and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2016.02.076.
AUTHOR CONTRIBUTIONS
S.Z. performed most of the experiments and helped design the study and
participated in writing the manuscript. Y.M., C.A., and J.I. performed in vivo
and ex vivo experiments. G.B. and J.M.B. designed and performed the
WWL70 and ABHD6-ASO in vivo experiments. P.P., D.Z., T.A.N., and R.P.
participated in genotyping and in vitro and respiration experiments. M.-L.P.
and E.J. participated in the design of in vivo experiments and interpretation
of the data. S.T. and S.F. designed and performed the behavior tests and in-
terpreted the results. S.R.M.M. andM.P. designed and supervised the project,
interpreted the data, and wrote the manuscript.2886 Cell Reports 14, 2872–2888, March 29, 2016 ª2016 The AuthorACKNOWLEDGMENTS
This study was supported by funds from Canadian Institutes of Health
Research grants to M.P. and S.R.M.M. and by a NIH grant (R01-HL122283)
to J.M.B. and a CIHR grant and New Investigator award to S.F. M.P. holds
the Canada Research Chair in Diabetes and Metabolism. Y.M. is supported
by a fellowship from Fond de recherche Sante´ Que´bec (FRSQ). We thank
the core facilities of Cellular Physiology & Metabolomics and Rodent
Phenotyping of CRCHUM/Montreal Diabetes Research Center for the
many metabolic analyses performed in this study. We also thank Dr. Julie
Lavoie, Dr. Ines Holzbaur, and Dr. Kathryn Skorey for critically reading the
manuscript.
Received: June 18, 2015
Revised: December 21, 2015
Accepted: February 18, 2016
Published: March 17, 2016
REFERENCES
Ahfeldt, T., Schinzel, R.T., Lee, Y.K., Hendrickson, D., Kaplan, A., Lum, D.H.,
Camahort, R., Xia, F., Shay, J., Rhee, E.P., et al. (2012). Programming human
pluripotent stem cells into white and brown adipocytes. Nat. Cell Biol. 14,
209–219.
Alhouayek, M., Masquelier, J., Cani, P.D., Lambert, D.M., and Muccioli, G.G.
(2013). Implication of the anti-inflammatory bioactive lipid prostaglandin D2-
glycerol ester in the control of macrophage activation and inflammation by
ABHD6. Proc. Natl. Acad. Sci. USA 110, 17558–17563.
Attane´, C., Daviaud, D., Dray, C., Dusaulcy, R., Masseboeuf, M., Pre´vot, D.,
Carpe´ne´, C., Castan-Laurell, I., and Valet, P. (2011). Apelin stimulates glucose
uptake but not lipolysis in human adipose tissue ex vivo. J. Mol. Endocrinol. 46,
21–28.
Attane´, C., Foussal, C., Le Gonidec, S., Benani, A., Daviaud, D., Wanecq, E.,
Guzma´n-Ruiz, R., Dray, C., Bezaire, V., Rancoule, C., et al. (2012). Apelin
treatment increases complete fatty acid oxidation, mitochondrial oxidative
capacity, and biogenesis in muscle of insulin-resistant mice. Diabetes 61,
310–320.
Badin, P.M., Loubie`re, C., Coonen, M., Louche, K., Tavernier, G., Bourlier, V.,
Mairal, A., Rustan, A.C., Smith, S.R., Langin, D., and Moro, C. (2012). Regula-
tion of skeletal muscle lipolysis and oxidative metabolism by the co-lipase
CGI-58. J. Lipid Res. 53, 839–848.
Bartelt, A., and Heeren, J. (2014). Adipose tissue browning and metabolic
health. Nat. Rev. Endocrinol. 10, 24–36.
Blankman, J.L., Simon, G.M., and Cravatt, B.F. (2007). A comprehensive pro-
file of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylgly-
cerol. Chem. Biol. 14, 1347–1356.
Cereijo, R., Giralt, M., and Villarroya, F. (2015). Thermogenic brown and beige/
brite adipogenesis in humans. Ann. Med. 47, 169–177.
Di Marzo, V., andMatias, I. (2005). Endocannabinoid control of food intake and
energy balance. Nat. Neurosci. 8, 585–589.
Dirkx, E., van Eys, G.J., Schwenk, R.W., Steinbusch, L.K., Hoebers, N., Cou-
mans, W.A., Peters, T., Janssen, B.J., Brans, B., Vogg, A.T., et al. (2014).
Protein kinase-D1 overexpression prevents lipid-induced cardiac insulin resis-
tance. J. Mol. Cell. Cardiol. 76, 208–217.
Even, P.C., and Nadkarni, N.A. (2012). Indirect calorimetry in laboratory mice
and rats: principles, practical considerations, interpretation and perspectives.
Am. J. Physiol. Regul. Integr. Comp. Physiol. 303, R459–R476.
Gnad, T., Scheibler, S., von K€ugelgen, I., Scheele, C., Kilic, A., Glo¨de, A., Hoff-
mann, L.S., Reverte-Salisa, L., Horn, P., Mutlu, S., et al. (2014). Adenosine ac-
tivates brown adipose tissue and recruits beige adipocytes via A2A receptors.
Nature 516, 395–399.
Haemmerle, G., Moustafa, T., Woelkart, G., B€uttner, S., Schmidt, A., van de
Weijer, T., Hesselink, M., Jaeger, D., Kienesberger, P.C., Zierler, K., et al.s
(2011). ATGL-mediated fat catabolism regulates cardiac mitochondrial func-
tion via PPAR-a and PGC-1. Nat. Med. 17, 1076–1085.
Hondares, E., Iglesias, R., Giralt, A., Gonzalez, F.J., Giralt, M., Mampel, T., and
Villarroya, F. (2011a). Thermogenic activation induces FGF21 expression and
release in brown adipose tissue. J. Biol. Chem. 286, 12983–12990.
Hondares, E., Rosell, M., Dı´az-Delfı´n, J., Olmos, Y., Monsalve, M., Iglesias, R.,
Villarroya, F., and Giralt, M. (2011b). Peroxisome proliferator-activated recep-
tor a (PPARa) induces PPARg coactivator 1a (PGC-1a) gene expression and
contributes to thermogenic activation of brown fat: involvement of PRDM16.
J. Biol. Chem. 286, 43112–43122.
Kharitonenkov, A., and Adams, A.C. (2014). Inventing new medicines: The
FGF21 story. Mol. Metab. 3, 221–229.
Koh, H.J., Toyoda, T., Didesch, M.M., Lee, M.Y., Sleeman, M.W., Kulkarni,
R.N., Musi, N., Hirshman, M.F., and Goodyear, L.J. (2013). Tribbles 3mediates
endoplasmic reticulum stress-induced insulin resistance in skeletal muscle.
Nat. Commun. 4, 1871.
Kohanski, R.A., Frost, S.C., and Lane, M.D. (1986). Insulin-dependent phos-
phorylation of the insulin receptor-protein kinase and activation of glucose
transport in 3T3-L1 adipocytes. J. Biol. Chem. 261, 12272–12281.
Lee, G., Elwood, F., McNally, J.,Weiszmann, J., Lindstrom,M., Amaral, K., Na-
kamura, M., Miao, S., Cao, P., Learned, R.M., et al. (2002). T0070907, a selec-
tive ligand for peroxisome proliferator-activated receptor gamma, functions as
an antagonist of biochemical and cellular activities. J. Biol. Chem. 277, 19649–
19657.
Liew, C.W., Bochenski, J., Kawamori, D., Hu, J., Leech, C.A., Wanic, K., Mal-
ecki, M., Warram, J.H., Qi, L., Krolewski, A.S., and Kulkarni, R.N. (2010). The
pseudokinase tribbles homolog 3 interacts with ATF4 to negatively regulate in-
sulin exocytosis in human and mouse beta cells. J. Clin. Invest. 120, 2876–
2888.
Liu, Q., Gauthier, M.S., Sun, L., Ruderman, N., and Lodish, H. (2010). Activa-
tion of AMP-activated protein kinase signaling pathway by adiponectin and in-
sulin in mouse adipocytes: requirement of acyl-CoA synthetases FATP1 and
Acsl1 and association with an elevation in AMP/ATP ratio. FASEB J. 24,
4229–4239.
Liu, S., Xi, Y., Bettaieb, A., Matsuo, K., Matsuo, I., Kulkarni, R.N., and Haj, F.G.
(2014). Disruption of protein-tyrosine phosphatase 1B expression in the
pancreas affects b-cell function. Endocrinology 155, 3329–3338.
Mauvais-Jarvis, F., Clegg, D.J., andHevener, A.L. (2013). The role of estrogens
in control of energy balance and glucose homeostasis. Endocr. Rev. 34,
309–338.
Mottillo, E.P., Bloch, A.E., Leff, T., and Granneman, J.G. (2012). Lipolytic prod-
ucts activate peroxisome proliferator-activated receptor (PPAR) a and d in
brown adipocytes to match fatty acid oxidation with supply. J. Biol. Chem.
287, 25038–25048.
Nadal-Casellas, A., Bauza´-Thorbr€ugge, M., Proenza, A.M., Gianotti, M., and
Llado´, I. (2013). Sex-dependent differences in rat brown adipose tissue mito-
chondrial biogenesis and insulin signaling parameters in response to an obe-
sogenic diet. Mol. Cell. Biochem. 373, 125–135.
Nedergaard, J., and Cannon, B. (2014). The browning of white adipose tissue:
some burning issues. Cell Metab. 20, 396–407.
Nielsen, T.S., Jessen, N., Jørgensen, J.O., Møller, N., and Lund, S. (2014). Dis-
secting adipose tissue lipolysis: molecular regulation and implications for
metabolic disease. J. Mol. Endocrinol. 52, R199–R222.
Nookaew, I., Svensson, P.A., Jacobson, P., Jerna˚s, M., Taube, M., Larsson, I.,
Andersson-Assarsson, J.C., Sjo¨stro¨m, L., Froguel, P., Walley, A., et al. (2013).
Adipose tissue resting energy expenditure and expression of genes involved in
mitochondrial function are higher in women than in men. J. Clin. Endocrinol.
Metab. 98, E370–E378.
Ohno, H., Shinoda, K., Spiegelman, B.M., and Kajimura, S. (2012). PPARg ag-
onists induce a white-to-brown fat conversion through stabilization of
PRDM16 protein. Cell Metab. 15, 395–404.
Owen, B.M., Ding, X., Morgan, D.A., Coate, K.C., Bookout, A.L., Rahmouni, K.,
Kliewer, S.A., and Mangelsdorf, D.J. (2014). FGF21 acts centrally to induceCellsympathetic nerve activity, energy expenditure, and weight loss. Cell Metab.
20, 670–677.
Peyot, M.L., Pepin, E., Lamontagne, J., Latour, M.G., Zarrouki, B., Lussier, R.,
Pineda, M., Jetton, T.L., Madiraju, S.R., Joly, E., and Prentki, M. (2010). Beta-
cell failure in diet-induced obesemice stratified according to body weight gain:
secretory dysfunction and altered islet lipid metabolism without steatosis or
reduced beta-cell mass. Diabetes 59, 2178–2187.
Pfeifer, A., and Hoffmann, L.S. (2015). Brown, beige, and white: the new color
code of fat and its pharmacological implications. Annu. Rev. Pharmacol. Tox-
icol. 55, 207–227.
Prentki, M., and Madiraju, S.R. (2008). Glycerolipid metabolism and signaling
in health and disease. Endocr. Rev. 29, 647–676.
Richard, D., Carpentier, A.C., Dore´, G., Ouellet, V., and Picard, F. (2010). De-
terminants of brown adipocyte development and thermogenesis. Int. J. Obes.
34 (Suppl 2), S59–S66.
Roberts, L.D., Bostro¨m, P., O’Sullivan, J.F., Schinzel, R.T., Lewis, G.D., Dejam,
A., Lee, Y.K., Palma, M.J., Calhoun, S., Georgiadi, A., et al. (2014). b-Aminoi-
sobutyric acid induces browning of white fat and hepatic b-oxidation and is
inversely correlated with cardiometabolic risk factors. Cell Metab. 19, 96–108.
Rosen, E.D., and Spiegelman, B.M. (2014). What we talk about when we talk
about fat. Cell 156, 20–44.
Shabalina, I.G., Petrovic, N., de Jong, J.M., Kalinovich, A.V., Cannon, B., and
Nedergaard, J. (2013). UCP1 in brite/beige adipose tissue mitochondria is
functionally thermogenic. Cell Rep. 5, 1196–1203.
Sharma, S., and Fulton, S. (2013). Diet-induced obesity promotes depressive-
like behaviour that is associated with neural adaptations in brain reward cir-
cuitry. Int. J. Obes. 37, 382–389.
Spiegelman, B.M. (2013). Banting Lecture 2012: Regulation of adipogenesis:
toward new therapeutics for metabolic disease. Diabetes 62, 1774–1782.
Sumara, G., Formentini, I., Collins, S., Sumara, I., Windak, R., Bodenmiller, B.,
Ramracheya, R., Caille, D., Jiang, H., Platt, K.A., et al. (2009). Regulation of
PKD by the MAPK p38delta in insulin secretion and glucose homeostasis.
Cell 136, 235–248.
Taschler, U., Radner, F.P., Heier, C., Schreiber, R., Schweiger, M., Schois-
wohl, G., Preiss-Landl, K., Jaeger, D., Reiter, B., Koefeler, H.C., et al. (2011).
Monoglyceride lipase deficiency in mice impairs lipolysis and attenuates
diet-induced insulin resistance. J. Biol. Chem. 286, 17467–17477.
Thomas, G., Betters, J.L., Lord, C.C., Brown, A.L., Marshall, S., Ferguson, D.,
Sawyer, J., Davis, M.A., Melchior, J.T., Blume, L.C., et al. (2013). The serine hy-
drolase ABHD6 Is a critical regulator of the metabolic syndrome. Cell Rep. 5,
508–520.
Wang, W., Lin, Q., Lin, R., Zhang, J., Ren, F., Zhang, J., Ji, M., and Li, Y. (2013).
PPARa agonist fenofibrate attenuates TNF-a-induced CD40 expression in
3T3-L1 adipocytes via the SIRT1-dependent signaling pathway. Exp. Cell
Res. 319, 1523–1533.
Wiernsperger, N.F. (2005a). Is non-insulin dependent glucose uptake a thera-
peutic alternative? Part 1: physiology, mechanisms and role of non insulin-
dependent glucose uptake in type 2 diabetes. Diabetes Metab. 31, 415–426.
Wiernsperger, N.F. (2005b). Is non-insulin dependent glucose uptake a thera-
peutic alternative? Part 2: Do such mechanisms fulfil the required combination
of power and tolerability? Diabetes Metab. 31, 521–525.
Wu, J., Bostro¨m, P., Sparks, L.M., Ye, L., Choi, J.H., Giang, A.H., Khandekar,
M., Virtanen, K.A., Nuutila, P., Schaart, G., et al. (2012). Beige adipocytes are a
distinct type of thermogenic fat cell in mouse and human. Cell 150, 366–376.
Wu, J., Cohen, P., and Spiegelman, B.M. (2013). Adaptive thermogenesis in
adipocytes: is beige the new brown? Genes Dev. 27, 234–250.
Xue, B., Coulter, A., Rim, J.S., Koza, R.A., and Kozak, L.P. (2005). Transcrip-
tional synergy and the regulation of Ucp1 during brown adipocyte induction
in white fat depots. Mol. Cell. Biol. 25, 8311–8322.
Zechner, R., Zimmermann, R., Eichmann, T.O., Kohlwein, S.D., Haemmerle,
G., Lass, A., and Madeo, F. (2012). FAT SIGNALS–lipases and lipolysis in lipid
metabolism and signaling. Cell Metab. 15, 279–291.Reports 14, 2872–2888, March 29, 2016 ª2016 The Authors 2887
Zhao, S., Mugabo, Y., Iglesias, J., Xie, L., Delghingaro-Augusto, V., Lussier, R.,
Peyot, M.L., Joly, E., Taı¨b, B., Davis, M.A., et al. (2014). a/b-Hydrolase domain-
6-accessible monoacylglycerol controls glucose-stimulated insulin secretion.
Cell Metab. 19, 993–1007.
Zhao, S., Pourshariffi, P., Mugabo, Y., Levens, E.J., Vivot, K., Attane, C., Igle-
sias, J., Peyot, M.L., Joly, E., Madiraju, S.R., and Prentki, M. (2015). a/b-Hy-2888 Cell Reports 14, 2872–2888, March 29, 2016 ª2016 The Authordrolase domain-6 and saturated long chain monoacylglycerol regulate insulin
secretion promoted by both fuel and non-fuel stimuli. Mol. Metab. 4,
940–950.
Zhu, L., Martinez, M.N., Emfinger, C.H., Palmisano, B.T., and Stafford, J.M.
(2014). Estrogen signaling prevents diet-induced hepatic insulin resistance in
malemice with obesity. Am. J. Physiol. Endocrinol. Metab. 306, E1188–E1197.s
